MonTa Biosciences ApS
π©π°Denmark
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: MBS8(1V270)
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- MonTa Biosciences ApS
- Target Recruit Count
- 69
- Registration Number
- NCT04855435
- Locations
- π§πͺ
Institut Jules Bordet, Anderlecht, Belgium
π©π°University Hospital of Denmark, Department of Oncology, Copenhagen, Denmark
π©π°Herlev and Gentofte Hospital, Center for Cancer Research, Herlev, Denmark
Β© Copyright 2025. All Rights Reserved by MedPath